On October 20, 2021, the FDA authorized the use of a heterologous (or “mix and match”) booster dose in eligible populations with currently available (i.e., FDA-authorized or approved) COVID-19 vaccines. 18 through 64 years of age with frequent institutional or occupational exposure to SARS-CoV-2.18 through 64 at high risk of severe COVID-19.

The vaccine also continues to be available under emergency use authorization (EUA), including for individuals 12 years of age and older, for the administration of a third dose in certain immunocompromised people, and for a single booster dose in people:

The vaccine has been known as the Pfizer-BioNTech COVID-19 Vaccine, and will now be marketed as Comirnaty, for the prevention of COVID-19 disease in individuals 16 years of age and older. On August 23, 2021, the FDA approved the first COVID-19 vaccine. Comirnaty Information Pfizer-BioNTech Fact Sheets Pfizer-BioNTech Fact Sheet Translations Información sobre las vacunas para el COVID-19